Updates
Cures For Hair Loss 2023 - News Feed
A very good idea is to bookmark this article page in your browser or mobile browser for easy access on the latest hair loss cure and hair growth treatment news. This will allow you to check it easily for updates. If you are looking for a corresponding article from a past update, simply use the “Search” function on this site to locate the article. As always, thanks for reading and please share this information with all you feel would benefit from it!
Triple Hair’s TH-07 Licensed By South Korean Pharma Co.
Triple Hair of Canada announced yesterday that their flagship drug candidate TH-07 has been licensed by Mother's Pharmaceutical of Korea. TH-07 is a combinatorial topical pharmaceutical product for hair regrowth comprising minoxidil, finasteride, and latanoprost. With the hair growth capability of those three ingredients well documented (especially with minoxidil and finasteride), the product stands to be a logical, albeit familiar, prescription treatment success. For the North American markets, TH-07 is still preparing to enter a pivotal phase 3 clinical trial, and the company's website iscurrently recruitingmale patients.
The recentlicensing agreementwith Mother's Pharmaceutical appears to have given Triple Hair ~$2.75M in an up-front payment, with potential milestone payments as part of the deal. This capital will likely be put towards the initiation of a phase 3 clinical trial in North America to seek widespread regulatory approval as a safe and effective treatment for hair loss.
Inmagene Starts Phase 2 Alopecia Areata Trial
The alopecia areata pipeline continues to expand with companies reaching the clinical trial stage; an overall good sign for hair-related diseases. Thistime, Inmagene Biopharmaceuticals has entered a phase 2a clinical trial for its antibody candidate IMG-007 in adults with moderate to severe alopecia areata. IMG-007 is a monoclonal antibody therapy against the 0x40 protein, and is it also happens to be in trials against atopic dermatitis.
IMG-007's alopecia areata trial participants will be dosed intravenously over the course of 6 months, and the study will be open label, meaning there is no placebo involved. More information about the trial, which is recruiting in October 2023, can be found on its officialclinical trial listing.
TrichoSeeds Co. & Fukuda Clinical Trial Start Update
Junji Fukuda PhD's hair cloning startup company, TrichoSeeds Co., is making news in the Japanese biotech sector these days. TrichoSeeds Co. has been selected as a finalist at the upcoming 5th Healthcare Venture Award event sponsored by the Japan Anti-Aging Association. Out of a pool of 34candidates, TrichoSeeds was selected to the panel of 7 finalists competing for a grand prize of 1 million yen. In the company description of TrichoSeeds Co. on the Healthcare Venture Award website, which would naturally be provided by the company themselves, there is an update mentioned about the timeline for the start of TrichoSeeds' first hair cloning trial. Head to the Articles page to read more ofthe detailsshared about this important clinical trial.
Alopecia Areata Pipeline Expands With Horizon Therapeutics’ Bempikibart
Horizon Therapeutics is a global pharmaceutical company with multiple candidates for alopecia areata in its portfolio. On September 13, 2023, Horizon announced that, in conjunction with its partner Q32 Bio, it had initiated a phase 2 clinical trial for bempikibart in adults with severe alopecia areata. Bempikibart (formerly known as ADX-914) is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP.
In addition, Horizon Therapeutics also has another drug candidate, daxdilimab, currently being trialed for AA atphase 2.
Epibiotech Interview EPI-001 Clinical Trial In 2023
2022世界杯附加赛预测英格兰vs美国皇冠比分卵泡认为published today a new interview with Epibiotech CEO Dr. Jong-Hyuk Sung. The topics covered include EPI-001 beginning its important phase 1 clinical trial in Korea, the Epibiotech pipeline, and alopecia areata therapies. Head to the Articles page, or if you are reading this long after its publication, search for "Epibiotech EPI-001 clinical trial" on this website to find the article.
Coegin Pharma To Develop Follicum’s FOL005 As Cosmetic
Coegin Pharma, the company which acquired Follicum several years ago, has new plans for the FOL005 peptide. After recently attempting to resurrect FOL005 from the clinical trials archive, the company has an even more ambitious plan for the compound - to market it as a cosmetic. This news was shared onCoegin's websitein August 2023. Apparently, discussions with industry partners helped sway Coegin's interests towards a cosmetic development route. The potential upsides are a much faster development track which would mean consumers get the treatment faster and the company generates revenue sooner. Below is a slide from Follicum's latest presentation.
If you had not previously seen it, Follicum also shared anew presentationwith the Follicle Thought audience in May 2023.
GT20029 Phase 2 China Trial Completes Male Patient Enrollment
The Kintor trial train keeps moving along. While we were once mesmerized by the thought of two AGA pipeline drugs moving to regulatory approval, expectations around pyrilutamide have likely decreased slightly, yet, hopes are still high for GT20029. In late August 2023, Kintor announced the completion of patient enrollment in its phase 2 trial for male AGA in China. This means, after the latest patients complete dosing, the trial will likely wrap up around the end of November.
Kintorofficials saytop line data is expected in Q1 2024. This will be our first look at GT20029's efficacy, which will be a meaningful and pivotal moment in the drug's development.
博士研究Verteporfin砰的一声头发移植的疤痕. Bloxham
A new documentation of a hair transplant surgeon studying the YAP inhibiting drug verteporfin in hair transplant surgery has been published on the front page. Dr. Blake Bloxham of New York has followed in the footsteps of Dr. Barghouthi in testing the application of verteporfin to the wounded scalp areas following hair transplant surgery. This work is being done to test the capacity for verteporfin to create scarless wound healing, and potentially, hair follicle regeneration in the donor extraction area.
Importantly, in the latest studies by Dr. Bloxham, verteporfin is being tested on FUT hair transplant wounds for the first time. Previously, verteporfin was only tested in microscopic FUE extraction wounds. An important update from Dr. Bloxham regarding the healing process of the FUT wounds can be expected around the end of September/early October. Follow the main article for further details.
StimuSIL Hair Growth Device Trial Listed On ClinicalTrials.Gov
Recently, you may have read about the newcomer device company, StimuSIL, on Follicle Thought. StimuSIL has created an innovation upon LLLT therapy with the hopes to create a treatment which is not only utilized, but respected, in the hair growth world. The first step in achieving that goal is to run a successful human clinical trial, which StimuSIL has embarked upon. A new listing onClinicalTrials.govreveals previously unknown details about the company's device.
New information about the StimuSIL SAGA device and trial format:
- Two device versions, SAGA-001 (A) and SAGA-001 (B) are being trialed.
- 38 adult males with androgenetic alopecia comprise the testing pool.
- Patients will receive 8 treatments over the course of 4 months (bi-weekly treatment).
- Primary outcome is the measured change in terminal hair density.
Carmell Therapeutics PRP Without Blood Draw
Earlier this week, Follicle Thought formally introduced a company developing an off the shelf version of platelet rich plasma for hair growth injections. Carmell Therapeutics is based in Pennslyvania, US and is planning to enter a large animal preclinical trial within the next several months. A clinical trial could follow shortly thereafter. Check the fullArticlefor more information.